TB Research

Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal

Shristy Ojha, Akash Adhikari, Sujan Adhikari, Swagat Khanal, Chandan Sah Kalwar, Om Prakash Panta

Microbiology Spectrum · 2026-03

Abstract

ABSTRACT Tuberculosis (TB) control in Nepal faces persistent challenges due to underdiagnosis and increasing drug resistance. This study assessed the diagnostic performance of the Xpert MTB/RIF assay compared with conventional smear microscopy and estimated the prevalence of rifampicin-resistant TB (RR-TB) in Biratnagar, a high-burden urban center. Between March and September 2023, 509 clinical specimens from TB suspects were analyzed by Ziehl-Neelsen (ZN) staining, fluorescence microscopy (FM), and Xpert MTB/RIF. Using Xpert as the operational reference, ZN and FM exhibited overall sensitivities of 55.9% (89/159) and 68.5% (109/159), respectively. In paired sputum-only analyses ( n = 446; sputum Xpert positives = 145), ZN and FM sensitivities were 60.0% (87/145) and 70.3% (102/145), respectively; sputum specificity was 100% for both methods. Xpert detected 31.2% (159/509) positive cases—78.7% more than ZN and 45.9% more than FM. Rifampicin resistance was identified in 5.03% (8/159) of Xpert-positive samples and was strongly associated with prior treatment ( P < 0.001); RR-TB occurred in 66.7% (6/9) of retreatment cases vs 1.3% (2/150) of new cases. Xpert increased detection in paucibacillary and extrapulmonary specimens. These findings support expanded use of rapid molecular testing, but results should be interpreted cautiously because culture/speciation was not performed. IMPORTANCE The spread of drug-resistant tuberculosis (TB) is a growing public health threat in Nepal. Using a rapid molecular test in Biratnagar, we simultaneously diagnosed TB and identified rifampicin resistance. We found rifampicin-resistant TB in >5% of Xpert-positive patients, higher than national averages for new cases, and a markedly elevated risk among previously treated patients. Rapid detection of resistance permits earlier initiation of appropriate therapy and can reduce onward transmission.

MeSH terms

  • Medicine
  • Sputum
  • Tuberculosis
  • Rifampicin
  • Mycobacterium tuberculosis
  • Internal medicine
  • Tuberculosis diagnosis
  • Tuberculosis control
  • Drug resistance
  • False positive paradox
  • Virology